Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trial Database Needed To Confirm Prozac Adolescent Benefit – JAMA

Executive Summary

A clinical trials database is necessary to help determine whether fluoxetine is the only SSRI that has beneficial effects in treating major depressive disorder in pediatric patients, a JAMA editorial says

You may also be interested in...

Clinical Trial Database Endorsed By PhRMA; Proposal Coming Soon

The Pharmaceutical Research & Manufacturers of America is endorsing the creation of an industry-wide database to disclose the results of clinical trials for pharmaceutical products

GSK Faces New York Suit Over Paxil: Publish Or Punish?

GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts